Pharmacological inhibition of EZH2 using EPZ005687 has been shown to reduce reactive oxygen species (ROS) generation and reverse H3K27me3‐mediated repression of SOD1 in the pulmonary vasculature, improving outcomes in models of PAH [229]. The gene discussed is EZH2; the disease is pulmonary arterial hypertension.